CN102215822A - 基于γ-羟基丁酸的新型组合物 - Google Patents

基于γ-羟基丁酸的新型组合物 Download PDF

Info

Publication number
CN102215822A
CN102215822A CN2009801457609A CN200980145760A CN102215822A CN 102215822 A CN102215822 A CN 102215822A CN 2009801457609 A CN2009801457609 A CN 2009801457609A CN 200980145760 A CN200980145760 A CN 200980145760A CN 102215822 A CN102215822 A CN 102215822A
Authority
CN
China
Prior art keywords
granule
hydroxybutyric acid
present
gamma
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801457609A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·勒邦
帕斯卡·祖普利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D & A Pharmaceuticals
Original Assignee
D & A Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40674006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102215822(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by D & A Pharmaceuticals filed Critical D & A Pharmaceuticals
Publication of CN102215822A publication Critical patent/CN102215822A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801457609A 2008-11-14 2009-11-10 基于γ-羟基丁酸的新型组合物 Pending CN102215822A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0857763A FR2938431B1 (fr) 2008-11-14 2008-11-14 Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR0857763 2008-11-14
PCT/FR2009/052169 WO2010055260A1 (fr) 2008-11-14 2009-11-10 Nouvelle composition à base d'acide gamma-hydroxybutyrique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510047649.3A Division CN104688691A (zh) 2008-11-14 2009-11-10 基于γ-羟基丁酸的新型组合物

Publications (1)

Publication Number Publication Date
CN102215822A true CN102215822A (zh) 2011-10-12

Family

ID=40674006

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801457609A Pending CN102215822A (zh) 2008-11-14 2009-11-10 基于γ-羟基丁酸的新型组合物
CN201510047649.3A Pending CN104688691A (zh) 2008-11-14 2009-11-10 基于γ-羟基丁酸的新型组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510047649.3A Pending CN104688691A (zh) 2008-11-14 2009-11-10 基于γ-羟基丁酸的新型组合物

Country Status (34)

Country Link
US (1) US8529954B2 (cg-RX-API-DMAC7.html)
EP (1) EP2349217B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012508784A (cg-RX-API-DMAC7.html)
KR (1) KR101563390B1 (cg-RX-API-DMAC7.html)
CN (2) CN102215822A (cg-RX-API-DMAC7.html)
AR (1) AR074351A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009315441B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916021B8 (cg-RX-API-DMAC7.html)
CA (1) CA2743767C (cg-RX-API-DMAC7.html)
CL (1) CL2011001114A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382106A2 (cg-RX-API-DMAC7.html)
CU (1) CU20110109A7 (cg-RX-API-DMAC7.html)
CY (1) CY1122209T1 (cg-RX-API-DMAC7.html)
DK (1) DK2349217T3 (cg-RX-API-DMAC7.html)
EA (1) EA023305B1 (cg-RX-API-DMAC7.html)
ES (1) ES2749803T3 (cg-RX-API-DMAC7.html)
FR (1) FR2938431B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20191911T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046321T2 (cg-RX-API-DMAC7.html)
IL (1) IL212847A (cg-RX-API-DMAC7.html)
LT (1) LT2349217T (cg-RX-API-DMAC7.html)
MA (1) MA32790B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005073A (cg-RX-API-DMAC7.html)
NZ (1) NZ592850A (cg-RX-API-DMAC7.html)
PE (1) PE20120028A1 (cg-RX-API-DMAC7.html)
PL (1) PL2349217T3 (cg-RX-API-DMAC7.html)
PT (1) PT2349217T (cg-RX-API-DMAC7.html)
SI (1) SI2349217T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900721T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000231A1 (cg-RX-API-DMAC7.html)
TW (1) TWI446906B (cg-RX-API-DMAC7.html)
UA (1) UA103057C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010055260A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103542B (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111317730A (zh) * 2013-03-01 2020-06-23 杰资制药爱尔兰有限公司 γ羟基丁酸与单羧酸转运蛋白的施用
CN112868909A (zh) * 2021-01-22 2021-06-01 湖北神舟化工有限公司 一种无臭型丁酸钠及其生产方法
WO2022218364A1 (en) * 2021-04-16 2022-10-20 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Coated beta hydroxybutyric acid crystal and methods for producing the same
CN117413958A (zh) * 2023-12-04 2024-01-19 湖北中烟工业有限责任公司 一种加热不燃烧烟草制品发烟段物料及其制作工艺和加热不燃烧烟草制品

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US20190183806A1 (en) * 2017-12-20 2019-06-20 Flamel Ireland Limited Packaged modified release gamma-hydroxybutyrate formulations having improved stability
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) * 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
AU2021292406B2 (en) * 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
KR102982616B1 (ko) 2020-06-18 2026-06-26 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) * 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
JP3447042B2 (ja) * 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
GB9725219D0 (en) 1997-11-29 1998-01-28 Cleansharp Ltd Tablets
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
WO2000038672A2 (en) * 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
JP2002544220A (ja) * 1999-05-17 2002-12-24 デー.ベー.エフ. 植物物質を含有する顆粒及びその製造方法
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
AU2002319774B2 (en) 2001-08-06 2005-04-21 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829933B3 (fr) 2001-09-21 2004-03-12 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
SI1551372T1 (en) * 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US20050214371A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
US20070092565A1 (en) 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
US9149434B2 (en) * 2007-12-03 2015-10-06 Tomita Pharmaceutical Co., Ltd. Core particle for pharmaceutical preparation
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111317730A (zh) * 2013-03-01 2020-06-23 杰资制药爱尔兰有限公司 γ羟基丁酸与单羧酸转运蛋白的施用
CN112868909A (zh) * 2021-01-22 2021-06-01 湖北神舟化工有限公司 一种无臭型丁酸钠及其生产方法
WO2022218364A1 (en) * 2021-04-16 2022-10-20 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Coated beta hydroxybutyric acid crystal and methods for producing the same
US20240033235A1 (en) * 2021-04-16 2024-02-01 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Coated beta hydroxybutyric acid crystal and methods for producing the same
US12569457B2 (en) * 2021-04-16 2026-03-10 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Coated beta hydroxybutyric acid crystal and methods for producing the same
CN117413958A (zh) * 2023-12-04 2024-01-19 湖北中烟工业有限责任公司 一种加热不燃烧烟草制品发烟段物料及其制作工艺和加热不燃烧烟草制品

Also Published As

Publication number Publication date
CA2743767C (fr) 2019-06-25
BRPI0916021A2 (pt) 2015-11-10
US8529954B2 (en) 2013-09-10
IL212847A0 (en) 2011-07-31
PT2349217T (pt) 2019-11-04
UA103057C2 (ru) 2013-09-10
HRP20191911T1 (hr) 2020-01-10
EA201100758A1 (ru) 2011-12-30
PL2349217T3 (pl) 2020-03-31
CO6382106A2 (es) 2012-02-15
AU2009315441B2 (en) 2015-02-26
ES2749803T3 (es) 2020-03-23
EP2349217A1 (fr) 2011-08-03
CN104688691A (zh) 2015-06-10
SI2349217T1 (sl) 2020-01-31
EA023305B1 (ru) 2016-05-31
PE20120028A1 (es) 2012-02-25
IL212847A (en) 2015-02-26
TN2011000231A1 (fr) 2012-12-17
SMT201900721T1 (it) 2020-01-14
BRPI0916021B1 (pt) 2020-01-14
WO2010055260A1 (fr) 2010-05-20
US20110293729A1 (en) 2011-12-01
LT2349217T (lt) 2019-11-11
CY1122209T1 (el) 2020-11-25
TWI446906B (zh) 2014-08-01
CA2743767A1 (fr) 2010-05-20
ZA201103542B (en) 2012-01-25
BRPI0916021B8 (pt) 2021-05-25
CU20110109A7 (es) 2012-01-31
NZ592850A (en) 2012-11-30
AR074351A1 (es) 2011-01-12
DK2349217T3 (da) 2019-11-04
AU2009315441A1 (en) 2010-05-20
JP2012508784A (ja) 2012-04-12
KR20110099011A (ko) 2011-09-05
CL2011001114A1 (es) 2011-09-02
HUE046321T2 (hu) 2020-02-28
FR2938431B1 (fr) 2013-12-20
FR2938431A1 (fr) 2010-05-21
EP2349217B1 (fr) 2019-07-31
MA32790B1 (fr) 2011-11-01
TW201031401A (en) 2010-09-01
MX2011005073A (es) 2011-10-12
KR101563390B1 (ko) 2015-11-06

Similar Documents

Publication Publication Date Title
CN104688691A (zh) 基于γ-羟基丁酸的新型组合物
IE902823A1 (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
JP2013501763A (ja) 薬物誤用に対する新規の医薬製剤
KR20130117761A (ko) 간단한 투약을 위한 인산염 결합제 조성물
HRP20000213A2 (en) Extended release formulation
JP2004507487A (ja) 腸疾患治療薬
CN101874783A (zh) 一种含有褪黑素的缓释制剂及其制备方法
EP0418597A2 (en) Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
CN101601659B (zh) 一种谷胱甘肽肠溶微丸及其制备方法
JPH0419969B2 (cg-RX-API-DMAC7.html)
GB2134785A (en) Slow-release compositions
CN102223879A (zh) 制备活性组分颗粒的新方法及所获得的颗粒
CN106822907B (zh) 一种含消旋卡多曲的双相释放制剂及其制备方法
CN102552107B (zh) 含唑吡坦或其盐的双相释放制剂及其制备方法
CN102755310A (zh) 一种含有左旋多巴的组合物药物制剂
CN1631395A (zh) 银杏叶缓释制剂及其制备方法
CN1175812C (zh) 吲哒帕胺缓释胶囊及其制备方法
CN100596276C (zh) 长春西汀缓释胶囊及其制备方法
CN101590038B (zh) 一种口服缓释降压组合物
CN101120931A (zh) 一种苯扎贝特缓释组合物
CN1989954A (zh) 酒石酸美托洛尔缓释胶囊及其制备方法
MX2014008975A (es) Composicion de nitazoxanida mejorada y proceso para prepararla.
CN102068418A (zh) 索法酮缓释微丸胶囊制剂及其制备方法
KR100501827B1 (ko) 다층 코팅법을 이용한 멜라토닌 함유 타게팅 약물 전달 기구
JP2024525962A (ja) 放出制御型経口製剤及びその調製方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111012